Natus Medical Incorporated
Period: Oct 16, 2015 to Apr 3, 2016
Lead Plaintiff Deadline: Mar 31, 2017
Summary of Case:
A securities class action has been filed against Natus Medical Incorporated ("Natus") (NASDAQ:BABY) on behalf of purchasers of Natus common stock during the period between October 16, 2015 through April 3, 2016. This case has been filed in the USDC - Northern District of California .
The complaint alleges that during the Class Period, defendants issued false and misleading statements and/or failed to disclose adverse information regarding the Company's business and prospects, including, among other things, that: (i) the Venezuelan government had failed to make tens of millions of dollars in prepayments to Natus, which were required to have been paid beginning in October 2015; (ii) Natus had no means to effectively enforce its rights under the Supply Contract, as Venezuela was the exclusive forum for dispute resolution; (iii) Natus's receipt of revenues pursuant to the Supply Contract was contingent on the outcome of Venezuelan elections; and (iv) as a result of the foregoing, Natus was not on track to achieve the increased guidance provided by defendants and such guidance lacked a reasonable basis. As a result of defendants' false and misleading statements, Natus stock traded at artificially inflated prices during the Class Period, reaching prices above $50 per share, and certain of the Company's senior executives were able to cash in $14.5 million worth of their personally held Natus shares at artificially inflated prices.
On January 11, 2016, Natus revealed that it expected to fall short of its fourth quarter and fiscal year 2015 guidance. The Company also disclosed that "[t]he guidance provided by the Company in October for the fourth quarter of 2015 included expected revenue of approximately $4 million under the new Venezuelan Ministry of Health contract," but "[t]he Company was not able to ship product on the anticipated schedule because the prepayment under the contract was delayed." On this revelation, the price of Natus common stock declined almost $5 per share, or 11%. On February 29, 2016, Natus filed its Annual Report on Form 10-K for fiscal year 2015 with the SEC, which disclosed that elections in Venezuela and Argentina and Venezuela's "highly inflationary economy and recessionary economic conditions" "may impact the likelihood of the Venezuelan Ministry of Health's following through with orders under the agreement, and [Natus's Argentinian subsidiary] ha[d] not yet received any prepayments under the agreement and no products or services ha[d] been shipped or provided." The Company attached a copy of the Supply Contract to the 10-K, which disclosed that $69 million in prepayments had been due by the end of 2015 and not the first quarter of 2016, as defendants had represented, and revealed that the Supply Contract was governed solely by Venezuelan law, meaning the Venezuelan government could unilaterally renege on all aspects of the agreement.
Then, on April 4, 2016, Natus issued a press release pre-announcing its preliminary first quarter 2016 results. The release disclosed that revenue would be below the Company's previous guidance and that Natus did not have "‘any revenue associated with the Venezuela Ministry of Health contract as [it] did not receive any prepayments during the quarter.'" On this news, the price of Natus stock declined $7.80 per share, or nearly 20%, to close at $31.84 per share on April 4, 2016.
If you purchased this company's shares during the Class Period and suffered a loss or for further information about the case, please review the links below.